These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 20535606)
1. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. de Villiers TJ; Chines AA; Palacios S; Lips P; Sawicki AZ; Levine AB; Codreanu C; Kelepouris N; Brown JP Osteoporos Int; 2011 Feb; 22(2):567-76. PubMed ID: 20535606 [TBL] [Abstract][Full Text] [Related]
2. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. Christiansen C; Chesnut CH; Adachi JD; Brown JP; Fernandes CE; Kung AW; Palacios S; Levine AB; Chines AA; Constantine GD BMC Musculoskelet Disord; 2010 Jun; 11():130. PubMed ID: 20569451 [TBL] [Abstract][Full Text] [Related]
3. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA; Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271 [TBL] [Abstract][Full Text] [Related]
4. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD; Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819 [TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129 [TBL] [Abstract][Full Text] [Related]
7. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA; Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306 [TBL] [Abstract][Full Text] [Related]
8. [Bazedoxifene as a new-generation SERM]. Ohta H Clin Calcium; 2011 Jan; 21(1):34-42. PubMed ID: 21187592 [TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Kawate H; Takayanagi R Clin Interv Aging; 2011; 6():151-60. PubMed ID: 21753870 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Palacios S Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824 [TBL] [Abstract][Full Text] [Related]
12. Safety assessment of raloxifene over eight years in a clinical trial setting. Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663 [TBL] [Abstract][Full Text] [Related]
13. The evolution of selective estrogen receptor modulators in osteoporosis therapy. Hadji P Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318 [TBL] [Abstract][Full Text] [Related]
14. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide. Palacios S; Currie H; Mikkola TS; Dragon E Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082 [TBL] [Abstract][Full Text] [Related]
15. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006 [TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Genant HK Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bazedoxifene in postmenopausal Asian women. Xu L; Tsai KS; Kim GS; Wu Y; Vincendon P; Chines AA; Constantine GD Osteoporos Int; 2011 Feb; 22(2):559-65. PubMed ID: 20535607 [TBL] [Abstract][Full Text] [Related]